Truist Cuts Boston Scientific (BSX) ’s Target as Doctors Change How They Use Its Heart Device

Boston Scientific (BSX) faces a notable headwind as Truist Securities reduced its price target by 24.7%, from $85 to $64, while maintaining a Buy rating. This mixed messaging—downside revision paired with bullish stance—suggests analyst conviction remains intact despite near-term demand deterioration. The 21-point gap signals caution on near-term catalysts.

The core issue centers on changing physician behavior around BSX's cardiac device portfolio. Rather than reflecting fundamental product weakness, the slowdown appears driven by shifts in clinical adoption patterns and possibly competitive intensity or reimbursement pressures. Such demand normalization is typical in medtech after strong growth phases, particularly as market saturation increases among target patient populations.

This represents a modest earnings-revision cycle rather than a structural crisis. Health Care stocks often experience multiple compression during demand modulation phases, though companies with diversified portfolios like BSX typically recover as new indications or adjacent markets activate. The analyst retention of Buy suggests BSX's valuation may eventually re-rate higher if utilization stabilizes.

Sector implication: Isolated medtech weakness does not signal broad Health Care sector vulnerability. Demand recalibration in one device category reflects normal market dynamics and may create entry points for long-term investors, though near-term volatility is likely as consensus estimates adjust downward.